Institutional investors purchased a net $2.9 million shares of HALO during the quarter ended September 2014 and now own 61.38% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
LOMBARD ODIER ASSET MANAGEMENT (... Bought 1.2 Million shares of Halozyme Therapeutics Inc